Table 3. Potential risk factors for reduction of LVEF after treatment with trastuzumab.

	LVEF baseline median (range)	LVEF end of treatment median (range)	P-value
	60.5 (43–72)	55.05 (24.8–72)	0.03
RT on cardiac area
Yes	62 (43–69)	52.5 (40–72)	0.08
No	60 (48–72)	61 (24.8–66)	0.18
HDCT
Single	60.5 (47–65)	60 (40–66)	0.83
Multiple	60.5 (43–72)	56.8 (24.8–72)	0.02
High-dose agents
No CTX,No DHAD	60.5 (53.2–64)	61 (24.8–66)	0.85
CTX	60 (43–72)	55.5 (45–72)	0.15
CTX+DHAD	60 (47–71)	58.1 (40–65)	0.11
Anthracycline
Yes	60 (43–72)	59.05 (24.8–72)	0.10
No	64 (61–71)	53.5 (40–65.4)	0.14
Trastuzumab
⩽12 months	60 (43–71)	58.1 (24.8–72)	0.31
>12months	61 (47–72)	60 (40–66)	0.07
Age (years)
<50	60 (43–72)	60 (40–66)	0.49
⩾50	65 (53.2–71)	52 (24.8–72)	0.02
LVEF baseline%
<55	52 (43–54)	45 (24.8–60)	0.73
⩾55	64 (55–72)	62 (40–72)	0.48

CTX=cyclophosphamide; DHAD=mitoxantron; LVEF=left ventricular ejection fraction.

P-value: Wilcoxon sign rank test. RT=radiation therapy.